VICTREX PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,288 GBX | +2.06% |
|
-0.62% | -15.37% |
| May. 23 | Victrex Secures SBTi Validation for Net-zero Targets | MT |
| May. 14 | Jefferies Keeps Victrex at Underperform, Trims PT | MT |
| Sales 2024 * | 307M 391M | Sales 2025 * | 330M 421M | Capitalization | 1.12B 1.43B |
|---|---|---|---|---|---|
| Net income 2024 * | 58M 73.9M | Net income 2025 * | 69M 87.91M | EV / Sales 2024 * | 3.64 x |
| Net cash position 2024 * | 4.23M 5.39M | Net cash position 2025 * | 22.89M 29.16M | EV / Sales 2025 * | 3.32 x |
| P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
16.3
x | Employees | 1,109 |
| Yield 2024 * |
4.64% | Yield 2025 * |
4.71% | Free-Float | 98.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Victrex plc
More press releases
More news
| 1 day | +2.06% | ||
| 1 week | -0.62% | ||
| 1 month | +1.74% | ||
| 3 months | +4.72% | ||
| 6 months | -11.96% | ||
| Current year | -15.37% |
1 week
1 242.76
1 316.00
1 month
1 210.001 368.00
Current year
1 152.001 545.00
1 year
1 152.001 632.00
3 years
1 152.002 720.00
5 years
1 152.002 720.00
10 years
1 152.003 438.06
| Managers | Title | Age | Since |
|---|---|---|---|
Jakob Sigurðsson
CEO | Chief Executive Officer | 60 | 17-08-31 |
Michael Ward
DFI | Director of Finance/CFO | - | - |
Ian Melling
DFI | Director of Finance/CFO | - | 22-07-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jakob Sigurðsson
CEO | Chief Executive Officer | 60 | 17-08-31 |
Dame Cox
CHM | Chairman | 64 | 21-11-30 |
Brendan Connolly
BRD | Director/Board Member | 68 | 18-02-08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 746 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 45 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1,288 | +2.06% | 339,165 |
| 24-05-30 | 1,262 | +0.32% | 111,815 |
| 24-05-29 | 1,258 | -2.48% | 68,704 |
| 24-05-28 | 1,290 | -0.46% | 75,555 |
| 24-05-24 | 1,296 | -.--% | 64,135 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotes
Victrex plc is a United Kingdom-based holding company. The principal activity of the Company is the manufacture and sale of high-performance polymers. The Company develops solutions in polyetheretherketone (PEEK) and polyaryletherketone (PAEK) based polymers and selects semi-finished and finished parts. The Company operates through two segments: Sustainable Solutions and Medical. The Sustainable Solutions segment focuses on its energy and industrial, value-added resellers (VAR), automotive, aerospace and electronics markets. The Medical segment is focused on providing specialist solutions for medical device manufacturers. The Companyâs subsidiaries include Victrex Manufacturing Limited, Invibio Limited, Invibio Knees Limited, Invibio Device Component Manufacturing Limited and Juvora Limited.
Sector
Specialty Chemicals
Calendar
2024-12-02
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
12.88
GBP
Average target price
14.75
GBP
Spread / Average Target
+14.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.37% | 1.43B | |
| +17.07% | 66.31B | |
| -0.29% | 48.46B | |
| +21.61% | 43.27B | |
| +26.72% | 27.41B | |
| +9.25% | 19.26B | |
| +9.75% | 16.58B | |
| -2.14% | 16.61B | |
| -15.01% | 14.41B | |
| -30.22% | 14.02B |
- Stock Market
- Equities
- VCT Stock
